Notwithstanding positive clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from PBMs. The insurers are frequently creating limitations to reimbursement, including high cost requirements and approval processes that limit consumer availability. Analysts